Michael J. Schell, PhD

Where You Are:
Michael J. Schell, PhD

Senior Member

"Statistical examination is critical to glean true biological differences from technological artifacts, providing patients the best personalized treatment."

Office  (813) 745-6061

Education And Training
  • PhD, Florida State University, 1984 - Statistics
  • MS, Florida State University, 1981 - Statistics
  • BS, University of North Carolina, 1979 - Mathematics
  • BA, University of North Carolina, 1979 - Sociology

Dr. Schell has led the development of a statistical method to analyze AQUA (Automated Quantitative Analysis)-generated tissue microarray (TMA) data. The method is a 7-step procedure which works quite well for identifying and resolving technical problems when two highly correlated variables are available.  This method provides a practical and efficient way of identifying an appropriate transformation (square-root, quarter-root or log), if needed, of AQUA scores that can be used to satisfy the normality assumption required by most of statistical procedures.  This methodology identifies and adjusts for possible row or column spatial bias effects in a 20 x 17 rectangular plate used in the AQUA machine, which arise due to technical processing effects. The method facilitates the identification of possible outliers or leverage data points in the data due to, for instance, air bubbles. Dr. Schell is a member of the Cancer Biomarkers Study Section.  He is also the statistician for a large integral-biomarker phase III multi-center clinical trial in lung cancer.

  • Rao NG, Trotti A, Kim J, Schell MJ, Zhao X, Amdur RJ, Brizel DM, Chambers MS, Caudell JJ, Miyamoto C, Rosenthal DI. Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. 2014 Aug;50(8):765-769. Pubmedid: 24954065.
  • Kothari N, Schell MJ, Teer JK, Yeatman T, Shibata D, Kim R. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. J Clin Pathol. 2014 Jul. Pubmedid: 25004944.
  • Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, Tetteh LF, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S. A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors. Clin Cancer Res. 2014 Mar;20(6):1644-1655. Pubmedid: 24429877.
  • Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol Syst Biol. 2014 Mar;9:705. Pubmedid: 24189400. Pmcid: PMC4039310.
  • Reich RR, Lengacher CA, Kip KE, Shivers SC, Schell MJ, Shelton MM, Widen RH, Newton C, Barta MK, Paterson CL, Farias JR, Cox CE, Klein TW. Baseline Immune Biomarkers as Predictors of MBSR(BC) Treatment Success in Off-Treatment Breast Cancer Patients. Biol Res Nurs. 2014 Jan. Pubmedid: 24477514.
  • Han G, Schell MJ, Kim J. Improved survival modeling in cancer research using a reduced piecewise exponential approach. Stat Med. 2014 Jan;33(1):59-73. Pubmedid: 23900779.
  • Lengacher CA, Reich RR, Kip KE, Barta M, Ramesar S, Paterson CL, Moscoso MS, Carranza I, Budhrani PH, Kim SJ, Park HY, Jacobsen PB, Schell MJ, Jim HS, Post-White J, Farias JR, Park JY. Influence of Mindfulness-Based Stress Reduction (MBSR) on Telomerase Activity in Women With Breast Cancer (BC). Biol Res Nurs. 2014 Jan. Pubmedid: 24486564.
  • Etzkorn JR, Parikh RP, Marzban SS, Law K, Davis AH, Rawal B, Schell MJ, Sondak VK, Messina JL, Rendina LE, Zager JS, Lien MH. Identifying risk factors using a skin cancer screening program. Cancer Control. 2013 Oct;20(4):248-254. Pubmedid: 24077401.
  • Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A. Phase II Trial of a GM-CSF-producing and CD40L-expressing Bystander Cell Line Combined With an Allogeneic Tumor Cell-based Vaccine for Refractory Lung Adenocarcinoma. J Immunother. 2013 Oct;36(8):442-450. Pubmedid: 23994887.
  • Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul;31(19):2404-2412. Pubmedid: 23690416. Pmcid: PMC3691357.
  • Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013 Mar;48(3):346-350. Pubmedid: 22863723.
  • Gray JE, Altiok S, Alexandrow MG, Walsh FW, Chen J, Schell MJ, Tai DF, Bepler G. Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers. Cancer. 2013 Mar;119(5):1023-1032. Pubmedid: 23065656. Pmcid: PMC3578040.
  • Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?. Sci Rep. 2013 Mar;2:765. Pubmedid: 23097687. Pmcid: PMC3479449.
  • Han G, Schell MJ, Kim J. Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test. Stat Biopharm Res. 2012 Oct;4(4):348-356. Pubmedid: 23814641.
  • Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012 Sep;23(9):2335-2341. Pubmedid: 22317769.
  • Knapp CF, Sayegh Z, Schell MJ, Rawal B, Ochoa T, Sondak VK, Messina JL. Expression of CXCR4, e-cadherin, bcl-2, and survivin in merkel cell carcinoma: an immunohistochemical study using a tissue microarray. Am J Dermatopathol. 2012 Aug;34(6):592-596. Pubmedid: 22814318.
  • Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 2012 May;118(9):2525-2531. Pubmedid: 22028294. Pmcid: PMC3270127.
  • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012 Mar;33(2):279-285. Pubmedid: 22101219. Pmcid: PMC3268882.
  • Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials. 2012 Jan;2(1). Pubmedid: 24533253. Pmcid: PMC3924733.
  • Pillai S, Rizwani W, Li X, Rawal B, Nair S, Schell MJ, Bepler G, Haura E, Coppola D, Chellappan S. ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol. 2011 Oct;31(14):3052-3067. Pubmedid: 21606196. Pmcid: PMC3133413.
  • Mahmood ST, Agresta S, Vigil C, Zhao X, Han G, D'Amato G, Calitri CE, Dean M, Garrett C, Schell MJ, Antonia S, Chiappori A. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer. 2011 Oct;129(8):1963-1969. Pubmedid: 21154746. Pmcid: PMC3776586.
  • Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ. Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol. 2011 Jun;64(6):583-593. Pubmedid: 21163620. Pmcid: PMC3079810.
  • Turaga KK, Malafa MP, Jacobsen PB, Schell MJ, Sarr MG. Suicide in patients with pancreatic cancer. Cancer. 2011 Feb;117(3):642-647. Pubmedid: 20824626.
  • Bepler G, Olaussen KA, Vataire AL, Soria JC, Zheng Z, Dunant A, Pignon JP, Schell MJ, Fouret P, Pirker R, Filipits M, Brambilla E. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol. 2011 Jan;178(1):69-78. Pubmedid: 21224045. Pmcid: PMC3069904.
  • Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, Schell MJ, Huang Y, Anasetti C, Perkins J. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant. 2010 Apr;45(4):662-667. Pubmedid: 19684623. Pmcid: PMC2850960.
  • Chiappori AA, Zheng Z, Chen T, Rawal B, Schell MJ, Mullaney BP, Bepler G. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol. 2010 Apr;5(4):484-490. Pubmedid: 20107425. Pmcid: PMC2861290.
  • Lee JH, Schell MJ, Roetzheim R. Analysis of group randomized trials with multiple binary endpoints and small number of groups. PLoS One. 2010 Mar;4(10):e7265. Pubmedid: 19844579. Pmcid: PMC2760209.
  • Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar;28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.
  • Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, Cognetti F, Bepler G. In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Invest. 2010 Feb;28(2):172-180. Pubmedid: 19968494. Pmcid: PMC3565222.
  • Chen JJ, Roberson PK, Schell MJ. The false discovery rate: a key concept in large-scale genetic studies. Cancer Control. 2010 Jan;17(1):58-62. Pubmedid: 20010520.
  • Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright G, Boehm KA, Asmar L, Bromund J, Peng G, Monberg MJ, Bepler G. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009 Dec;27(34):5808-5815. Pubmedid: 19884554. Pmcid: PMC2793001.
  • Lee J-H, Miladinovic B, Schell MJ. Statistical tutorial notes: analysis of two group comparisons, a practical guide. Med Probl Perform Art. 2009 Dec;166-169.
  • Gao J, Zheng Z, Rawal B, Schell MJ, Bepler G, Haura EB. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol Ther. 2009 Sep;8(17):1671-1679. Pubmedid: 19633423. Pmcid: PMC3839311.
  • Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, Schell MJ, Coppola D, Cheng JQ. Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol. 2009 Jul;175(1):324-333. Pubmedid: 19497997. Pmcid: PMC2708818.
  • Barami K, Sloan AE, Rojiani A, Schell MJ, Staller A, Brem S. Relationship of gliomas to the ventricular walls. J Clin Neurosci. 2009 Feb;16(2):195-202. Pubmedid: 19097905.
  • Hozo I, Schell M, Djulbegovic B. Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach. Semin Hematol. 2008 Jul;45(3):150-159. Pubmedid: 18582621.
  • Zheng Z, Li X, Schell M, Chen T, Boulware D, Robinson L, Sommers E, Bepler G. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer. 2008 Jun;112(12):2765-2773. Pubmedid: 18442042. Pmcid: PMC3857609.
  • Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008 May;112(9):2021-2029. Pubmedid: 18300255.
  • Tanvetyanon T, Robinson L, Schell M, Strong V, Kapoor R, Coit D, BeplerG. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrena metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008 Mar;26(7):1142-1147. Pubmedid: 18309950.
  • Chen DT, Schell MJ, Chen JJ, Fulp WJ, Eschrich S, Yeatman T. A predictive risk probability approach for microarray data with survival as an endpoint. J Biopharm Stat. 2008;18(5):841-852. Pubmedid: 18781520. Pmcid: PMC2717790.
  • Schell M, Yankaskas B, Ballard-Barbash R, Qaqish B, Barlow W, RosenbergRD, Smith-Bindman R. Evidence-based Target Recall Rates for Screening Mammography. Radiology. 2007 Jun;243(3):681-689. Pubmedid: 17517927.
  • Pavic D, Schell M, Dancel R, Sultana S, Lin L, Sejpal S, Pisano E. Comparison of three methods to increase knowledge about breast cancer and breast cancer screening in screening mammography patients. Acad Radiol. 2007 May;14(5):553-560. Pubmedid: 17434069.
  • Lloyd-Burton SM, Yu JC, Irvine RF, Schell MJ. Regulation of inositol 1,4,5-trisphosphate 3-kinases by calcium and localization in cells. J Biol Chem. 2007 Mar;282(13):9526-9535. Pubmedid: 17284449.
  • Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006 Dec;108(12):3881-3889. Pubmedid: 16917002. Pmcid: PMC1895461.
  • Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang X, Lovell MA, Williams SA, Dawson TL, Schell MJ, Anwar AA, Snodgrass HR, Earp HS. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2006 May;12(9):2662-2669. Pubmedid: 16675557.
  • Stinchcombe T, Choi J, Schell M, Mears A, Jones P, Nachtsheim R, Socinski M. Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. Lung Cancer. 2006 Feb;51(2):237-243. Pubmedid: 16378657.
  • Titus M, Schell M, Lih F, Tomer K, Mohler J. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005 Jul;11(13):4653-4657. Pubmedid: 16000557.
  • Ivanova A, Qaqish B, Schell M. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 2005 Jun;61(2):540-545. Pubmedid: 16011702.
  • Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol. 2005 Jun;28(3):270-276. Pubmedid: 15923800.
  • Kondo S, Wakisaka N, Schell MJ, Horikawa T, Sheen TS, Sato H, Furukawa M, Pagano JS, Yoshizaki T. Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int J Cancer. 2005 Jun;115(3):368-376. Pubmedid: 15688379.
  • Titus MA, Gregory CW, Ford OH , Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res. 2005 Jun;11(12):4365-4371. Pubmedid: 15958619.
  • Hensing T, Schell M, Lee J, Socinski M. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005 Feb;47(2):253-259. Pubmedid: 15639724.
  • Mohler J, Gaston K, Moore D, Schell M, Cohen B, Weaver C, Petrusz P. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol. 2004;171(6-1):2277-2280. Pubmedid: 15126802.
  • Yankaskas B, Schell M, Miglioretti D. Recall and detection rates in screening mammography. Cancer. 2004;101(11):2710-2712. Pubmedid: 15499596.
  • Hensing T, Peterman A, Schell M, Lee J, Socinski M. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003 Aug;98(4):779-788. Pubmedid: 12910523.
  • Socinski MA, Neubauer MA, Olivares J, Ketchel S, Tynan M, Moore M, Lee JH, Davis K, Schell M, Garfield D. Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer. Lung Cancer. 2003 Apr;40(1):91-97. Pubmedid: 12660013.
  • Abrahamson P, Dunlap L, Amamoo M, Schell M, Braeuning M, Pisano E. Factors predicting successful needle-localized breast biopsy. Acad Radiol. 2003;10(6):601-606. Pubmedid: 12809412.
  • Bloedon LT, Jeffcoat AR, Lopaczynski W, Schell MJ, Black TM, Dix KJ, Thomas BF, Albright C, Busby MG, Crowell JA, Zeisel SH. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr. 2002 Nov;76(5):1126-1137. Pubmedid: 12399289.
  • McHale M, Berman M, Keefe K, Schell M, Peng Y, Monk B. Influence of Serum and Tissue Micronutrient Levels on the Regression of Untreated Cervical Intraepithelial Neoplasia 2 and 3. J Low Genit Tract Dis. 2002 Oct;6(4):220-224. Pubmedid: 17051026.
  • Socinski M, Schell M, Bakri K, Peterman A, Lee J, et al.. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer. 2002 Sep;95(6):1265-1273. Pubmedid: 12216094.
  • Socikski M, Schell M, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee J, et al.. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002 Mar;20(5):1335-1343. Pubmedid: 11870177.
  • Kidd JF, Pilkington MF, Schell MJ, Fogarty KE, Skepper JN, Taylor CW, Thorn P. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem. 2002 Feb;277(8):6504-6510. Pubmedid: 11724773.
  • Poole ME, Sailer SL, Rosenman JG, Tepper JE, Weissler MC, Shockley WW, Yarbrough WG, Pillsbury HC, Schell MJ, Bernard SA. Chemoradiation for locally advanced squamous cell carcinoma of the head and neck for organ preservation and palliation. Arch Otolaryngol Head Neck Surg. 2001 Dec;127(12):1446-1450. Pubmedid: 11735812.
  • Keefe KA, Schell MJ, Brewer C, McHale M, Brewster W, Chapman JA, Rose GS, McMeeken DS, Lagerberg W, Peng YM, Wilczynski SP, Anton-Culver H, Meyskens FL, Berman ML. A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1029-1035. Pubmedid: 11588128.
  • Charles MJ, Schell MJ, Willman E, Gross HB, Lin Y, Sonnenberg S, Graham ML. Organochlorines and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in cancerous and noncancerous breast tissue: do the data support the hypothesis that oxidative DNA damage caused by organochlorines affects breast cancer?. Arch Environ Contam Toxicol. 2001 Oct;41(3):386-395. Pubmedid: 11503078.
  • Socinski MA, Rosenman JG, Halle J, Schell MJ, Lin Y, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer. 2001 Sep;92(5):1213-1223. Pubmedid: 11571735.
  • Socinski MA, Rosenman JG, Schell MJ, Halle J, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial. Cancer. 2000 Aug;89(3):534-542. Pubmedid: 10931452.
  • Koizumi S, Bootman MD, Bobanović LK, Schell MJ, Berridge MJ, Lipp P. Characterization of elementary Ca2+ release signals in NGF-differentiated PC12 cells and hippocampal neurons. Neuron. 1999 Jan;22(1):125-137. Pubmedid: 10027295.
  • Cooper DM, Schell MJ, Thorn P, Irvine RF. Regulation of adenylyl cyclase by membrane potential. J Biol Chem. 1998 Oct;273(42):27703-27707. Pubmedid: 9765307.
  • Atiba JO, Manzardo AM, Thiruvengadam R, Schell MJ, Meyskens FL. Restoration of oral all-trans retinoic acid bioavailability after a brief drug holiday. Am J Ther. 1997 Apr;4(4):134-140. Pubmedid: 10423603.
  • Eliasson MJ, Blackshaw S, Schell MJ, Snyder SH. Neuronal nitric oxide synthase alternatively spliced forms: prominent functional localizations in the brain. Proc Natl Acad Sci U S A. 1997 Apr;94(7):3396-3401. Pubmedid: 9096405. Pmcid: PMC20381.
  • Manetta A, Schubbert T, Chapman J, Schell MJ, Peng YM, Liao SY, Meyskens FJ. beta-Carotene treatment of cervical intraepithelial neoplasia: a phase II study. Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):929-932. Pubmedid: 8922303.
  • Wilder-Smith P, Arrastia AM, Schell MJ, Liaw LH, Grill G, Berns MW. Effect of ND:YAG laser irradiation and root planing on the root surface: structural and thermal effects. J Periodontol. 1995 Dec;66(12):1032-1039. Pubmedid: 8683415.
  • Schell MJ, Molliver ME, Snyder SH. D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc Natl Acad Sci U S A. 1995 Apr;92(9):3948-3952. Pubmedid: 7732010. Pmcid: PMC42079.
  • Dinerman JL, Dawson TM, Schell MJ, Snowman A, Snyder SH. Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity. Proc Natl Acad Sci U S A. 1994 May;91(10):4214-4218. Pubmedid: 7514300. Pmcid: PMC43755.
  • Santana VM, Schell MJ, Williams R, Bowman LC, Thompson EI, Brenner MK, Mirro J. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors. Bone Marrow Transplant. 1992 Nov;10(5):457-462. Pubmedid: 1464010.
  • Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood. 1992 Jun;79(11):2849-2854. Pubmedid: 1375115.
  • Santana VM, Mirro J, Kearns C, Schell MJ, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992 Mar;10(3):364-370. Pubmedid: 1346800.
  • Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther. 1991 Sep;50(3):308-313. Pubmedid: 1680593.
  • Evans WE, Schell MJ, Pui CH. MTX clearance is more important for intermediate-risk ALL. J Clin Oncol. 1990 Jun;8(6):1115-1116. Pubmedid: 2348226.
  • Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, Meyer WH. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol. 1989 Jun;7(6):754-760. Pubmedid: 2715805.
  • Carter M, Kalwinsky DK, Dahl GV, Santana VM, Mason CA, Schell MJ. Childhood acute promyelocytic leukemia: a rare variant of nonlymphoid leukemia with distinctive clinical and biologic features. Leukemia. 1989 Apr;3(4):298-302. Pubmedid: 2927178.
  • Parkinson JF, Akard LP, Schell MJ, Gabig TG. Cell-free activation of phagocyte NADPH-oxidase: tissue and differentiation-specific expression of cytosolic cofactor activity. Biochem Bioph Res Co. 1987 Jun;145(3):1198-1204. Pubmedid: 3038092.
  • Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987 Jun;316(26):1627-1632. Pubmedid: 3495732.
  • Gabig TG, English D, Akard LP, Schell MJ. Regulation of neutrophil NADPH oxidase activation in a cell-free system by guanine nucleotides and fluoride. Evidence for participation of a pertussis and cholera toxin-insensitive G protein. J Biol Chem. 1987 Feb;262(4):1685-1690. Pubmedid: 3027097.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions